The doses of the epigenetic drugs active in combination were extremely low, in contrast to those reported in ALS studies employing individual molecules, where the modulation of the enzymatic activity of HDAC requires a very high concentration. The gene discussed is HDAC9; the disease is amyotrophic lateral sclerosis.